Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

Myeloproliferative neoplasms: A decade of discoveries and treatment advances

(2015) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

(2015) C. Al Assaf et al.   HAEMATOLOGICA

Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice

(2015) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

(2015) T Barbui et al.   Blood Cancer Journal

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

(2015) S Cerquozzi et al.   Blood Cancer Journal

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

(2015) C. Al Assaf et al.   HAEMATOLOGICA

Myeloproliferative Neoplasms

(2015) Ayalew Tefferi et al.   JAMA Oncology

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients

(2014) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

(2014) A. Tefferi et al.   BLOOD

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

(2014) A. Tefferi et al.   BLOOD

Calreticulin mutations and long-term survival in essential thrombocythemia

(2014) A Tefferi et al.   LEUKEMIA

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

(2014) A Tefferi et al.   LEUKEMIA

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study

(2012) Malin Hultcrantz et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY